IDEXX Laboratories, Inc. $IDXX Shares Sold by Chevy Chase Trust Holdings LLC

Chevy Chase Trust Holdings LLC cut its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 40,845 shares of the company’s stock after selling 1,636 shares during the period. Chevy Chase Trust Holdings LLC owned 0.05% of IDEXX Laboratories worth $26,095,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of IDXX. WealthCollab LLC purchased a new stake in IDEXX Laboratories during the 2nd quarter worth about $30,000. J.Safra Asset Management Corp acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth about $31,000. Armstrong Advisory Group Inc. increased its holdings in shares of IDEXX Laboratories by 55.9% in the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after acquiring an additional 19 shares during the last quarter. Salomon & Ludwin LLC purchased a new position in shares of IDEXX Laboratories in the 3rd quarter valued at about $35,000. Finally, Greykasell Wealth Strategies Inc. acquired a new stake in shares of IDEXX Laboratories during the 3rd quarter worth about $35,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Trading Up 2.2%

NASDAQ:IDXX opened at $586.37 on Tuesday. The company has a market capitalization of $46.69 billion, a PE ratio of 44.86, a P/E/G ratio of 3.48 and a beta of 1.66. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $769.98. The stock’s 50 day moving average price is $656.25 and its 200 day moving average price is $666.45. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The firm had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. IDEXX Laboratories’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insider Activity

In related news, Director Sophie V. Vandebroek sold 1,464 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total transaction of $920,299.68. Following the completion of the sale, the director owned 648 shares in the company, valued at $407,345.76. This represents a 69.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP George Fennell sold 11,345 shares of the firm’s stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the transaction, the executive vice president directly owned 9,823 shares in the company, valued at $6,352,730.56. The trade was a 53.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 45,957 shares of company stock worth $29,862,109 over the last 90 days. 0.98% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Piper Sandler cut their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. BTIG Research reduced their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Weiss Ratings cut shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Finally, UBS Group cut their price target on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 3rd. Seven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $783.33.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.